The 1999 National Cancer Institute Prostate Cancer Progress Review Group Report stated clearly that ?understanding the biology of prostate cancer? is a ?national priority? in battling this cancer which kills approximately 32,000 men annually. In our preliminary data, we demonstrate that we have completed Specific Aims 1-3 and identified that protease activated receptor 1 (PAR1, thrombin receptor) expression is upregulated in prostate cancer as compared to normal prostate epithelial tissue and is poised to play a central role in prostate cancer tumorigenesis and metastasis. Specifically, we demonstrate: A) The development of bone-derived and dura-derived prostate cancer cell (PC) lines as tools to investigate this hypothesis. B) cDNA microarray analysis of normal prostate versus prostate cancer primary tumors, metastatic tumors, and prostate cancer cell lines reveals that PAR1 is overexpressed in prostate cancer, especially those cell lines derived from bone metastases. C) Confirmation of this overexpression by rt-PCR, Northern, and Western analyses. D) Activation of PAR1 increases prostate cancer cell motility. E) Activation of PAR1 increases prostate cancer cell invasion. Our hypothesis, therefore, is that PAR1 activation increases metastasis of prostate cancer cells. To investigate our hypothesis, we have developed the following Specific Aims:
Specific Aim 1 : Investigate the mechanism by which PAR1 activation stimulates prostate cancer cell motility.
Specific Aim 1 A: Investigate the intracellular G-protein pathways involved in PAR1-stimulated motility.
Specific Aim 2 : Investigate the mechanism by which PAR1 activation stimulates prostate cancer cell invasion.
Specific Aim 2 A: Investigate the intracellular G-protein pathways involved in PAR1 stimulated invasion. We believe that these experiments will prove that PAR1 activation plays a critical role in prostate cancer metastasis. Furthermore, these experiments will begin to delineate the mechanism of action of this role, both functionally as well as the intracellular pathways that may be involved. Ultimately, PAR1 may prove to be a target for prostate cancer metastasis prevention and treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA093900-05
Application #
7614523
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-05-01
Budget End
2009-04-30
Support Year
5
Fiscal Year
2008
Total Cost
$250,766
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Chalfin, Heather J; Glavaris, Stephanie A; Malihi, Paymaneh D et al. (2018) Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. J Urol 199:1494-1501
Axelrod, Haley D; Pienta, Kenneth J; Valkenburg, Kenneth C (2018) Optimization of Immunofluorescent Detection of Bone Marrow Disseminated Tumor Cells. Biol Proced Online 20:13
Jung, Younghun; Cackowski, Frank C; Yumoto, Kenji et al. (2018) CXCL12? Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes. Cancer Res 78:2026-2039
Decker, A M; Taichman, L S; D'Silva, N J et al. (2018) Periodontal Treatment in Cancer Patients: An Interdisciplinary Approach. Curr Oral Health Rep 5:7-12
Miller, Dannah R; Tzeng, Cherng-Chyi; Farmer, Trey et al. (2018) Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer. Cancer Lett 436:96-108
Machioka, Kazuaki; Izumi, Kouji; Kadono, Yoshifumi et al. (2018) Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines. Oncotarget 9:16185-16196
Hill, Elliott E; Kim, Jin Koo; Jung, Younghun et al. (2018) Integrin alpha V beta 3 targeted dendrimer-rapamycin conjugate reduces fibroblast-mediated prostate tumor progression and metastasis. J Cell Biochem 119:8074-8083
Axelrod, Haley D; Valkenburg, Kenneth C; Amend, Sarah R et al. (2018) AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer. Mol Cancer Res :
de Groot, Amber E; Pienta, Kenneth J (2018) Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages. Oncotarget 9:20908-20927
Roca, Hernan; Jones, Jacqueline D; Purica, Marta C et al. (2018) Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. J Clin Invest 128:248-266

Showing the most recent 10 out of 228 publications